AbbVie acquires Aliada Therapeutics for $1.4 billion to boost Alzheimer's drug pipeline
qz.com — October 28, 2024, 04:01 PM UTC
AbbVie is acquiring Aliada Therapeutics for $1.4 billion, which includes the experimental Alzheimer’s drug ALIA-1758. This move aims to enhance AbbVie's neuroscience pipeline after it halted its own Alzheimer’s treatment earlier this year. ALIA-1758 targets amyloid beta, a protein linked to Alzheimer’s. The drug will utilize Aliada’s technology to improve delivery across the blood-brain barrier, addressing a common challenge in developing central nervous system therapies. This acquisition comes as other companies, like Eli Lilly and Biogen, are also advancing their Alzheimer’s treatments. Novo Nordisk is testing its diabetes drug semaglutide for potential effects on early Alzheimer’s disease.